Growth and collaboration: Embracing new challenges facing China’s life sciences market
The Chinese government continues to invest in reforming its healthcare ecosystem. A key element of these reforms is the essential drug list (EDL), intended to reduce drug costs. The new EDL environment will create challenges and opportunities for pharmaceutical companies, pharmaceutical distributors and hospitals, as well as trigger changes in how they operate and compete. Integration and collaboration supported by information sharing will be required across four areas: new differentiated services development, operational excellence, sales effectiveness and supply chain optimization.
To find out more, download the IBM Institute for Business Value report: “Growth and collaboration: Embracing new challenges facing China’s life sciences market."
- Download the complete IBM Institute for Business Value study: "Growth and collaboration: Embracing new challenges facing China’s life sciences market” (1.9MB)